127 related articles for article (PubMed ID: 38598725)
1. Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL.
Gentile G; Poggio T; Catalano A; Voutilainen M; Lahnalampi M; Andrade-Martinez M; Ma T; Sankowski R; Goncharenko L; Tholen S; Han K; Morgens DW; Prinz M; Lübbert M; Engel S; Hartmann TN; Cario G; Schrappe M; Lenk L; Stanulla M; Duyster J; Bronsert P; Bassik MC; Cleary ML; Schilling O; Heinäniemi M; Duque-Afonso J
Blood Adv; 2024 Jun; 8(11):2846-2860. PubMed ID: 38598725
[TBL] [Abstract][Full Text] [Related]
2. E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.
Duque-Afonso J; Lin CH; Han K; Wei MC; Feng J; Kurzer JH; Schneidawind C; Wong SH; Bassik MC; Cleary ML
Cancer Res; 2016 Dec; 76(23):6937-6949. PubMed ID: 27758892
[TBL] [Abstract][Full Text] [Related]
3. [Identification of proteins associated with transcription factors HOXA9 and E2A-PBX1 by tandem affinity purification].
Shestakova EA; Boutin M; Bourassa S; Bonneil E; Bijl JJ
Mol Biol (Mosk); 2017; 51(3):490-501. PubMed ID: 28707666
[TBL] [Abstract][Full Text] [Related]
4. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.
Duque-Afonso J; Feng J; Scherer F; Lin CH; Wong SH; Wang Z; Iwasaki M; Cleary ML
J Clin Invest; 2015 Sep; 125(9):3667-80. PubMed ID: 26301816
[TBL] [Abstract][Full Text] [Related]
5. Direct and indirect targets of the E2A-PBX1 leukemia-specific fusion protein.
Diakos C; Xiao Y; Zheng S; Kager L; Dworzak M; Wiemels JL
PLoS One; 2014; 9(2):e87602. PubMed ID: 24503810
[TBL] [Abstract][Full Text] [Related]
6. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
7. Hoxa9 collaborates with E2A-PBX1 in mouse B cell leukemia in association with Flt3 activation and decrease of B cell gene expression.
Hassawi M; Shestakova EA; Fournier M; Lebert-Ghali CÉ; Vaisson G; Frison H; Sinnett D; Vidal R; Thompson A; Bijl JJ
Dev Dyn; 2014 Jan; 243(1):145-58. PubMed ID: 23996689
[TBL] [Abstract][Full Text] [Related]
8. Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia.
Izraeli S; Henn T; Strobl H; Ludwig WD; Kovar H; Haas OA; Harbott J; Bartram CR; Gadner H; Lion T
Leukemia; 1993 Dec; 7(12):2054-6. PubMed ID: 8255105
[TBL] [Abstract][Full Text] [Related]
9. Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.
Uckun FM; Qazi S; Dibirdik I; Myers DE
Integr Biol (Camb); 2013 Jan; 5(1):122-32. PubMed ID: 22990208
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X
Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861
[TBL] [Abstract][Full Text] [Related]
11. GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia.
Holmlund T; Lindberg MJ; Grander D; Wallberg AE
Leukemia; 2013 Mar; 27(3):578-85. PubMed ID: 23044487
[TBL] [Abstract][Full Text] [Related]
12. The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials.
Kamps MP; Look AT; Baltimore D
Genes Dev; 1991 Mar; 5(3):358-68. PubMed ID: 1672117
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: characterization and diagnostic utility.
Sang BC; Shi L; Dias P; Liu L; Wei J; Wang ZX; Monell CR; Behm F; Gruenwald S
Blood; 1997 Apr; 89(8):2909-14. PubMed ID: 9108411
[TBL] [Abstract][Full Text] [Related]
14. beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells.
Nygren MK; Døsen-Dahl G; Stubberud H; Wälchli S; Munthe E; Rian E
Exp Hematol; 2009 Feb; 37(2):225-33. PubMed ID: 19101069
[TBL] [Abstract][Full Text] [Related]
15. E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.
Pi WC; Wang J; Shimada M; Lin JW; Geng H; Lee YL; Lu R; Li D; Wang GG; Roeder RG; Chen WY
Blood; 2020 Jul; 136(1):11-23. PubMed ID: 32276273
[TBL] [Abstract][Full Text] [Related]
16. [Correlation of E2a-pbx1 expression level with clinical characteristics and early response to treatment in children with acute lymphoblastic leukemia].
Gao C; Li ZG; Zhao W; Wu MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):569-73. PubMed ID: 18549631
[TBL] [Abstract][Full Text] [Related]
17. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
18. Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth.
Lee YL; Ito K; Pi WC; Lin IH; Chu CS; Malik S; Cheng IH; Chen WY; Roeder RG
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33542097
[TBL] [Abstract][Full Text] [Related]
19. Identification of cooperative genes for E2A-PBX1 to develop acute lymphoblastic leukemia.
Sera Y; Yamasaki N; Oda H; Nagamachi A; Wolff L; Inukai T; Inaba T; Honda H
Cancer Sci; 2016 Jul; 107(7):890-8. PubMed ID: 27088431
[TBL] [Abstract][Full Text] [Related]
20. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K; Puła B
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
